Daraxonrasib for Pancreatic Cancer: How It Works and What New Trials Show — Nov. 21, 2026

Information checked: November 20, 2026, at 8:03 p.m. UTC (November 21 at 3:03 a.m. Indochina Time, UTC+07:00). The latest trial update was presented November 20 at the EORTC-NCI-AACR Symposium in Barcelona, Spain (Central European Time, UTC+01:00).

The experimental pancreatic cancer pill in the latest trial update is daraxonrasib, also known as RMC-6236. New Phase 1/2 data presented at the symposium showed tumour shrinkage in 60.7% of 61 people with metastatic pancreatic adenocarcinoma who received daraxonrasib with two chemotherapy drugs as first-line treatment. The results are encouraging, but they do not yet prove the combination is better than chemotherapy: this was an early-phase study without a randomized comparison group. A larger Phase 3 trial is testing that question.

Highlights

  • Daraxonrasib is an oral RAS(ON) inhibitor designed to interrupt active RAS cancer signals inside cells.
  • In an early Phase 1/2 combination study, 60.7% of 61 patients had tumours shrink or disappear; 8.2% had a complete response.
  • Median progression-free survival was 12.8 months, but the single-arm study cannot establish how much of that outcome was caused by the drug combination.
  • Phase 3 RASolute 303 is comparing daraxonrasib alone, the combination, and chemotherapy in first-line metastatic disease; a Canadian trial listing is available.
Researcher in a laboratory examining a vial and reviewing study notes
Illustrative photo of laboratory research; it does not depict the trial, a participant, or daraxonrasib.

How does daraxonrasib work?

RAS proteins act like switches that help regulate cell growth. In some cancers, a mutation leaves RAS signalling active, encouraging cells to keep growing. Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, is frequently driven by RAS mutations. Daraxonrasib is designed to interfere with the active, or “ON,” form of RAS rather than targeting just one particular KRAS mutation.

The drug enters a cell and binds to cyclophilin A, an intracellular protein. That pair then forms a three-part complex with active RAS. The complex blocks RAS from engaging downstream signalling partners and can help shift RAS toward its inactive state. In plain language, the approach aims to interrupt a growth signal that cancer cells use. It is a targeted mechanism, but it does not guarantee that every tumour depends on the same signal or will respond.

Daraxonrasib is taken orally in the study, but the regimen reported at the symposium also included gemcitabine and nab-paclitaxel, which are given by intravenous infusion. The trial therefore tested a pill-plus-chemotherapy strategy, not a pill-only treatment.

What did the latest trial report find?

The RMC-GI-102 Phase 1/2 study evaluated daraxonrasib with gemcitabine and nab-paclitaxel as an initial treatment for metastatic pancreatic adenocarcinoma. The EORTC report says 61 patients had received the combination by September 28, 2026; median follow-up was 18.3 months. Tumours shrank or became undetectable in 60.7% of patients, including complete responses in 8.2%. The disease-control rate was 90.2%, meaning the cancer either shrank or did not meet the study’s criteria for growth. Median progression-free survival, the time before cancer progressed or the patient died, was 12.8 months. The reported 12-month overall survival rate was 76.6%.

Those figures describe this group under this study’s conditions. A complete response means no detectable tumour on assessment; it is not the same as a proven cure. Likewise, progression-free survival and an estimated one-year survival rate in a small study should not be read as a promise for an individual patient.

The most commonly reported adverse effects included rash, diarrhea, fatigue, and low blood-cell counts associated with chemotherapy. The symposium report said treatment discontinuation due to daraxonrasib-related side effects was infrequent, at 5%. Side effects depend on the full regimen and patient; the study team monitored and managed them medically.

What do the trials still need to prove?

The key limitation is the design: RMC-GI-102 was an early-phase, open-label study, and the reported combination group was not randomly compared with patients receiving chemotherapy alone. The results cannot determine whether daraxonrasib itself accounts for the response rate or longer disease control compared with standard treatment. The study was sponsored by Revolution Medicines, the drug’s developer.

Phase 3 RASolute 303 is designed to provide a stronger comparison. Its registry describes a global, randomized study with three groups: daraxonrasib alone, daraxonrasib plus gemcitabine and nab-paclitaxel, or the chemotherapy combination alone. It is studying first-line treatment for metastatic pancreatic adenocarcinoma. The trial record lists an estimated primary completion in 2028, so confirmatory results are not yet available. Health Canada’s Clinical Trials Database also lists the RASolute 303 study in Canada; a trial listing means a study has been authorized to run, not that the treatment is generally approved or available.

The U.S. Food and Drug Administration announced approval of daraxonrasib in August 2026 for a specific group of adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, or who are not candidates for multi-agent systemic therapy. That U.S. decision does not itself establish Canadian authorization, and it does not approve the first-line chemotherapy combination described in the newer report. Canadian patients should check current Health Canada information and discuss treatment or trial options with their oncology team.

What should patients and families take from the results?

The data point to a promising research direction: blocking active RAS with an oral drug may deepen or prolong tumour control when paired with chemotherapy. The next meaningful step is to see whether the randomized Phase 3 trial confirms a benefit in outcomes such as progression-free or overall survival, and to understand the combination’s risks over a larger population. Until then, the Phase 1/2 percentages are preliminary clinical evidence, not a new standard of care for every patient with pancreatic cancer.

For trial details, use the original EORTC-NCI-AACR trial update, the sponsor’s Phase 1/2 data announcement, and the ClinicalTrials.gov RASolute 303 record. The National Cancer Institute’s drug entry describes the mechanism, and the Canadian Clinical Trials Database listing provides Canadian trial information. The FDA approval notice sets out the U.S. indication.

FAQ

Is daraxonrasib a chemotherapy drug?

No. It is an oral targeted RAS inhibitor. The latest first-line study combined it with the chemotherapy drugs gemcitabine and nab-paclitaxel.

Does a complete response mean the pancreatic cancer is cured?

No. It means no tumour was detectable using the study’s assessments at that time. It does not establish that cancer cells are gone permanently.

Can patients in Canada get daraxonrasib?

Canada lists a clinical trial studying the drug, but trial participation depends on eligibility and site availability. A trial listing is not a general marketing authorization; patients should ask their oncologist and check current Health Canada records.

Leave a Comment

GTA 6 Gameplay and Features: What’s Confirmed as of November 21, 2026

GTA 6 Gameplay and Features: What’s Confirmed as of November 21, 2026

See what Rockstar has confirmed about GTA 6 gameplay, Jason and Lucia, Leonida’s locations, platforms, visuals, and features—and what remains undisclosed.

How to Protect Your Superannuation From AI Phone Scams | November 21, 2026

How to Protect Your Superannuation From AI Phone Scams | November 21, 2026

An AI-generated call about superannuation highlights risks from cold callers and scams. Learn how to verify callers, protect account details, and act if you shared information.

GTA VI Is Out Now: Platforms, Story and What Comes Next — 20 November 2026

GTA VI launched on PS5 and Xbox Series X|S on 19 November. Here is what Australian players need to know about availability, the story, PC status and next steps.

Ellen Fanning’s AI Superannuation Call: What Australians Need to Know on November 20

An AI caller targeting Ellen Fanning’s super details has been reported across Australia. Here’s what the latest reporting and official guidance say to do.

How AI Voice Calls Could Put Australian Super at Risk

An AI caller named Alex has cold-called Australians about switching super funds. Learn how lead generation works and how to protect your retirement savings.

UK Emergency Preparedness: Household Essentials You Actually Need | November 20, 2026

UK Emergency Preparedness: Household Essentials You Actually Need | November 20, 2026

Build a practical three-day UK emergency kit with water, no-cook food, light, medicines, and a plan—without panic buying or waste.

Billie Eilish Confirmed for BST Hyde Park 2027: July 3 Date and Ticket Prices

Billie Eilish is confirmed for BST Hyde Park on July 3, 2027. See current ticket prices, presale and general sale dates, and what is still to be announced.

BST Hyde Park 2027: Headliners, Tickets and Confirmed Dates

Bon Jovi, Muse, Billie Eilish and RAYE are among BST Hyde Park 2027’s confirmed headliners. See dates, ticket prices, sale details and what is still to come.

UK Emergency Stockpiling: Essential Grocery Sales Jump After Be Ready Advice | Nov. 20, 2026

UK Emergency Stockpiling: Essential Grocery Sales Jump After Be Ready Advice | Nov. 20, 2026

UK emergency-preparedness purchases rose after Be Ready advice. See the latest grocery sales data, what it measures, and what the government actually recommends.

Why UK Shoppers Are Stocking Up on Groceries: What the Latest Data Shows (November 20, 2026)

UK food-store sales rose in October as shoppers bought more long-life groceries after the Be Ready campaign. Here’s what the data and official advice mean.